Differential usefulness of biomarkers thymus and activation-regulated chemokine and soluble CD30 during enteric coated mycophenolate sodium and cyclosporine therapy in atopic dermatitis.
Kwakkel-van Erp
Johanna M
JM
Haeck
Inge M
IM
Paantjens
Annelieke W M
AW
van de Graaf
Ed A
EA
van Ginkel
Walter G J
WG
Knol
Mirjam J
MJ
de Bruin-Weller
Marjolein S
MS
Lammers
Jan-Willem J
JW
Knol
Edward F
EF
Bruijnzeel-Koomen
Carla
C
Otten
Henny G
HG
D015415:Biomarkers / Q000097:blood; D054414:Chemokine CCL17 / Q000032:analysis / Q000097:blood*; D016572:Cyclosporine / Q000627:therapeutic use*; D003876:Dermatitis, Atopic / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D017730:Ki-1 Antigen / Q000032:analysis / Q000097:blood*; D008297:Male; D009173:Mycophenolic Acid / Q000627:therapeutic use*; D015588:Observer Variation; D010865:Pilot Projects; D011379:Prognosis; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D016037:Single-Blind Method; D013608:Tablets, Enteric-Coated; D016896:Treatment Outcome
D015415:Biomarkers; D054414:Chemokine CCL17; D017730:Ki-1 Antigen; D013608:Tablets, Enteric-Coated; D016572:Cyclosporine; D009173:Mycophenolic Acid